Cargando…
S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428327/ http://dx.doi.org/10.1097/01.HS9.0000967704.23014.16 |
| _version_ | 1785090441895477248 |
|---|---|
| author | Kastritis, Efstathios Palladini, Giovanni Dimopoulos, Meletios A. Jaccard, Arnaud Merlini, Giampaolo Theodorakakou, Foteini Fotiou, Despina Minnema Minnema, Monique C. Wechalekar, Ashutosh Papachristou, Elena Manousou, Kyriaki Sonneveld, Pieter Schönland, Stefan |
| author_facet | Kastritis, Efstathios Palladini, Giovanni Dimopoulos, Meletios A. Jaccard, Arnaud Merlini, Giampaolo Theodorakakou, Foteini Fotiou, Despina Minnema Minnema, Monique C. Wechalekar, Ashutosh Papachristou, Elena Manousou, Kyriaki Sonneveld, Pieter Schönland, Stefan |
| author_sort | Kastritis, Efstathios |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428327 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104283272023-08-17 S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK Kastritis, Efstathios Palladini, Giovanni Dimopoulos, Meletios A. Jaccard, Arnaud Merlini, Giampaolo Theodorakakou, Foteini Fotiou, Despina Minnema Minnema, Monique C. Wechalekar, Ashutosh Papachristou, Elena Manousou, Kyriaki Sonneveld, Pieter Schönland, Stefan Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428327/ http://dx.doi.org/10.1097/01.HS9.0000967704.23014.16 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Kastritis, Efstathios Palladini, Giovanni Dimopoulos, Meletios A. Jaccard, Arnaud Merlini, Giampaolo Theodorakakou, Foteini Fotiou, Despina Minnema Minnema, Monique C. Wechalekar, Ashutosh Papachristou, Elena Manousou, Kyriaki Sonneveld, Pieter Schönland, Stefan S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_full | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_fullStr | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_full_unstemmed | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_short | S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK |
| title_sort | s198: efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: a phase 2 study by the european myeloma network |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428327/ http://dx.doi.org/10.1097/01.HS9.0000967704.23014.16 |
| work_keys_str_mv | AT kastritisefstathios s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT palladinigiovanni s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT dimopoulosmeletiosa s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT jaccardarnaud s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT merlinigiampaolo s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT theodorakakoufoteini s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT fotioudespina s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT minnemaminnemamoniquec s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT wechalekarashutosh s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT papachristouelena s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT manousoukyriaki s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT sonneveldpieter s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork AT schonlandstefan s198efficacyandsafetyofbelantamabmafodotinmonotherapyinpatientswithrelapsedorrefractorylightchainamyloidosisaphase2studybytheeuropeanmyelomanetwork |